Menu Search
Equities

Merck & Co Inc

MRK:NYQ

Merck & Co Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)99.86
  • Today's Change2.42 / 2.48%
  • Shares traded15.67m
  • 1 Year change-2.30%
  • Beta0.4055
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 19-Nov-24
Select bar for recommendation details.
Recommendations19-Nov-24
Buy7
Outperform16
Hold7
Sell0
Strong Sell0

Share price forecast in USD

The 26 analysts offering 12 month price targets for Merck & Co Inc have a median target of 134.00, with a high estimate of 155.00 and a low estimate of 100.00. The median estimate represents a 37.52% increase from the last price of 97.44.
High59.1%155.00
Med37.5%134.00
Low2.6%100.00

Dividends in USD

In 2023, Merck & Co Inc reported a dividend of 2.96 USD, which represents a 5.71% increase over last year. The 6 analysts covering the company expect dividends of 3.02 USD for the upcoming fiscal year, an increase of 1.96%.
Div growth (TTM)5.71%
More ▼

Earnings history & estimates in USD

On Oct 31, 2024, Merck & Co Inc reported 3rd quarter 2024 earnings of 1.57 per share. This result was in line with the consensus of the 15 analysts following the company and under-performed last year's 3rd quarter results by 26.29%.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate+1,670.10%
Merck & Co Inc reported annual 2023 earnings of 1.51 per share on Feb 01, 2024.
Average growth rate-8.85%
More ▼

Revenue history & estimates in USD

Merck & Co., Inc. had 3rd quarter 2024 revenues of 16.66bn. This bettered the 16.46bn consensus of the 15 analysts covering the company. This was 14.98% above the prior year's 3rd quarter results.
Average growth rate+1.25%
Merck & Co., Inc. had revenues for the full year 2023 of 60.12bn. This was 1.40% above the prior year's results.
Average growth rate+7.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.